[11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy.
about
Update on positron emission tomography for imaging of prostate cancerBone imaging in prostate cancer: the evolving roles of nuclear medicine and radiologyImaging metabolic heterogeneity in cancerPET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data.Update on advances in molecular PET in urological oncologyOligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options.Management of urological malignancies: Has positron emission tomography/computed tomography made a difference?Clinical Indications of C-Choline PET/CT in Prostate Cancer Patients with Biochemical Relapse.Distribution Features of Skeletal Metastases: A Comparative Study between Pulmonary and Prostate Cancers.Functional imaging for prostate cancer: therapeutic implications.Molecular imaging of prostate cancer: PET radiotracers.Translational Molecular Imaging of Prostate Cancer.Management of metastatic castration-resistant prostate cancer: recent advances.18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients.Choline PET/CT for imaging prostate cancer: an update.Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis.Imaging biomarkers in prostate cancer: role of PET/CT and MRI.Initial prostate cancer diagnosis and disease staging--the role of choline-PET-CT.Imaging and evaluation of patients with high-risk prostate cancer.Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.PET imaging for lymph node dissection in prostate cancer.Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer.A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancDiagnostic performance of 11C-choline PET/CT and bone scintigraphy in the detection of bone metastases in patients with prostate cancer.Sensitivity and specificity of PET/CT regarding the detection of lymph node metastases in prostate cancer recurrence.Comparison of distribution characteristics of metastatic bone lesions between breast and prostate carcinomas.When to perform positron emission tomography/computed tomography or radionuclide bone scan in patients with recently diagnosed prostate cancer.Role of ¹⁸F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer.Prostate-specific antigen kinetics parameters are predictive of positron emission tomography features worsening in patients with biochemical relapse after prostate cancer treatment with radical intent: Results from a longitudinal cohort study.Current status of theranostics in prostate cancer.Antitumor T cell reconditioning: improving metabolic fitness for optimal cancer immunotherapy.The use of PET/CT in prostate cancer.Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer.Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis.Detection of local recurrence of prostate cancer after radical prostatectomy: Is there a role for early ¹⁸F-FCH PET/CT?Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases.2013: another good year for EJNMMI.Trigger pSA predicting recurrence from positive choline PET/CT with prostate cancer after initial treatment.
P2860
Q27026828-DA4094E5-B411-45C3-8EEB-D75E970A9ABFQ28071705-9446DBE0-BE4E-4AA5-A6D1-62D3D266B8C9Q28076500-A76C5238-96E2-471D-B6DA-9142B7778404Q31003607-25A8414C-0439-42EA-896A-F8F4FD9C7BEDQ33625389-0DA938D6-D7D7-4150-819B-26AC01640C16Q34748629-B6DFA864-E1CD-4275-92C5-5765D76EB742Q34990800-A4CEEF6D-AB6A-4B36-BA8A-478937695D5AQ35849174-F4E68577-5570-4DC3-A548-F03EEDBDA123Q35850043-3BA18D5B-BF8F-45AA-B4C5-C886FCABE578Q36128629-F45412BA-076B-474B-85A2-999630821807Q36129937-5989AA87-002F-4854-8710-890E434EB8B9Q37244969-30F72057-FF8F-427E-9653-957C56DBFF66Q38012528-943C77A3-BF3B-4A25-93AB-9CD173228DDEQ38098441-F8DC0471-49B9-41A0-9B45-DD01CD94EB1EQ38103180-54E8A135-D2D4-470F-B21A-B6947F7FF377Q38212848-11A4C4EC-D9BF-4122-9143-576446D80258Q38321182-A0D0DE6A-9025-449A-AD2B-5BFAFF3FE7ECQ38564109-E8BB3F29-587D-435B-91A2-A042F83EDF94Q38611187-B7BB113A-F9C7-4A2F-A69A-CD676801E225Q38766102-51069ECF-B71F-4265-BAAC-6DE2FA4FB3BEQ38983526-72642415-8C95-47BF-B19B-F49C4D9BF362Q39690658-D53A76C0-7B79-429B-9AB4-008AD82AF028Q40735810-87DFDD5D-995D-42A8-AB1F-D8E64F9147A3Q41161118-874A3B40-5E9B-4139-B6C2-FA5FE8EE2069Q41482900-ED172CF4-E242-479C-9FFF-B8DB598019E7Q41563753-95C65676-EF5F-49D2-84EE-724E4D78C594Q41827640-BC47540F-5800-4330-8761-0F07175E681DQ41903039-336F5AD2-2DCA-48E4-8B09-FB1DD9D9F3F5Q42088489-9A8224B8-63C1-4ACF-B4BF-16527323FE37Q45760116-AABB14F7-5780-4117-BA0C-8AEC762568EDQ45992756-83C24314-03F1-4AB6-9F65-7F71AE08EBCCQ47241139-C72B4926-2EC2-458F-B05F-B8CF99FEDF50Q49546319-F91C891F-2F46-4ECF-A75D-3E4415DC9562Q49919217-7DF4D55D-420B-4265-8498-58DA319B8A14Q52983467-7B812DBF-ADAE-4E7B-AF0B-538B9FBA20BAQ52990619-5C799EEB-6FD0-426B-9951-33345728DD5DQ52991811-5EE7B9A7-0622-4B59-8FBE-5DE0A7B0DDEEQ53682227-01B9BEC2-000D-4A0A-8B24-4F8446FF88E3Q54672079-E79FCDB5-8C4D-4957-9908-76D50B827DF2Q55188040-3FA400B5-D1F3-48FE-9FC4-81C30A85F8F8
P2860
[11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
[11C]Choline PET/CT detection ...... arison with bone scintigraphy.
@en
[11C]Choline PET/CT detection ...... arison with bone scintigraphy.
@nl
type
label
[11C]Choline PET/CT detection ...... arison with bone scintigraphy.
@en
[11C]Choline PET/CT detection ...... arison with bone scintigraphy.
@nl
prefLabel
[11C]Choline PET/CT detection ...... arison with bone scintigraphy.
@en
[11C]Choline PET/CT detection ...... arison with bone scintigraphy.
@nl
P2093
P2860
P1476
[11C]Choline PET/CT detection ...... arison with bone scintigraphy.
@en
P2093
Cristina Messa
Elena Giulia Spinapolice
Federico Fallanca
Giampiero Giovacchini
Luigi Gianolli
P2860
P2888
P356
10.1007/S00259-011-1920-Z
P577
2011-09-20T00:00:00Z
P6179
1027634743